Metabolic Dysfunction-associated Steatohepatitis (MASH)
ORIGINAL PAPER
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Expected trial readout: 2026-09-23
What the evidence supports so far
Research signals
Classification pending.
What remains unverified
The full methodology, effect size, and limitations still require analyst review.
Company impact remains unverified until a direct economic transmission is established.